• RepliCel Life Sciences Inc., of Vancouver, British Columbia, said it closed a $1.3 million private placement of 876,042 units priced at $1.50 apiece. Each unit consisted of one common share and one common share purchase warrant. An initial tranche of 66,304 units for gross proceeds of $99,456 closed Feb. 29, and the firm expects to close one or more tranches in the coming weeks at the same $1.50 per unit price. Proceeds will be used for general working requirements. RepliCel is developing autologous cell transplantation technology to treat hair loss.